Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline

NBIX is a biopharmaceutical company that discovers, develops, and markets drugs to treat neurological, neuroendocrine, and neuropsychiatric disorders. The company’s first-quarter fiscal 2026 earnings report showed over $800 million in net product sales, led by INGREZZA’s 44% year-over-year growth, net income of around $200 million, and a strong product pipeline (12 current programs with five more slated for launch this year).

It’s no wonder NBIX shares are up 27% this year, and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Neurocrine Attracting Institutional Capital

Institutional volumes reveal plenty. In the last year, NBIX has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in NBIX shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Neurocrine.

Neurocrine Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, NBIX has had strong sales and earnings growth:

• 3-year sales growth rate (+24.3%)
• 3-year EPS growth rate (+44.3%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +27%.

Now it makes sense why the stock has been generating Big Money interest. NBIX has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Neurocrine has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

In the last few months, NBIX has drawn four outlier inflow signals. The blue bars below show when NBIX was a top pick on the Outlier 20 report in the last decade…Big Money is a believer:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Neurocrine Price Prediction

The NBIX action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in NBIX at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.